Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.71 |
| ▸ | FNTB | P49356 | 13/20 | 0.71 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7204928 | 0.92 | FNTA (0.69) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL7210859 | 0.85 | FNTA (0.70) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL7203361 | 0.83 | FNTA (1.00) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL1682772 | 0.81 | FNTA (1.00) | FNTAFNTB | |
| SCHEMBL13928075 | 0.81 | FNTA (1.00) | FNTAFNTB | |
| SCHEMBL7210118 | 0.80 | FNTA (1.00) | FNTAFNTBPGGT1BRORC | |
| Hydrochloric Acid SCHEMBL6435591 | 0.80 | FNTA (0.98) | FNTAFNTB | |
| SCHEMBL5783981 | 0.80 | FNTA (0.68) | FNTAFNTBRORC | |
| SCHEMBL5654543 | 0.79 | FNTA (0.96) | FNTAFNTB | |
| SCHEMBL3494162 | 0.79 | FNTA (0.78) | FNTAFNTBPGGT1BRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0970079-B1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-01 | — | — | EP | disclosed |
| US-6444812-B1 | SUCH AS 7-(3-CHLOROPHENYL)-9-((4-CHLOROPHENYL)-1H-IMIDAZOL-1-YLMETHYL)-2,3-DIHYDRO -1H,5H-BENZO(IJ) QUINOLIZIN-5-ONE; FOR FORMING ONCOGENES FOR SIGNALLING TRANSFORMATION OF TUMOR CELLS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-03 | — | — | US | disclosed |
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | VENET MARC GASTON (FR) | 2002-04-25 | — | — | US | disclosed |
| US-6187786-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | HCCS, CYP7A1, DHCR7 | FNTA 4/4885FNTB 5/4885PGGT1B 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.